oral

Vantage Biosciences Doses First Patient in Phase 2 Clinical Study of Oral VX-01 for Non-Proliferative Diabetic RetinopathyVantage Biosciences Doses First Patient in Phase 2 Clinical Study of Oral VX-01 for Non-Proliferative Diabetic Retinopathy

Vantage Biosciences Doses First Patient in Phase 2 Clinical Study of Oral VX-01 for Non-Proliferative Diabetic Retinopathy

LONDON, April 11, 2025 (GLOBE NEWSWIRE) -- Vantage Biosciences, a clinical stage biotechnology company advancing innovative therapies for diabetic eye…

2 weeks ago
Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimers DiseaseAnavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimers Disease

Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimers Disease

ATTENTION-AD trial data through 192 weeks presented at AD/PDTM 2025 Conference Prespecified delayed-start analysis indicate disease-modifying effect of oral blarcamesine…

2 weeks ago
Novo Nordisk A/S: Rybelsus (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025Novo Nordisk A/S: Rybelsus (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025

Novo Nordisk A/S: Rybelsus (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025

Rybelsus® reduced major adverse cardiovascular events by 14% vs placebo in adults with type 2 diabetes and cardiovascular and/or chronic…

3 weeks ago
Novartis receives third FDA approval for oral Fabhalta (iptacopan) the first and only treatment approved in C3 glomerulopathy (C3G)Novartis receives third FDA approval for oral Fabhalta (iptacopan) the first and only treatment approved in C3 glomerulopathy (C3G)

Novartis receives third FDA approval for oral Fabhalta (iptacopan) the first and only treatment approved in C3 glomerulopathy (C3G)

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)…

1 month ago
A Happy Mouth Is a Happy Mind: FDI World Dental Federation features new song to raise awareness of the link between oral health and mental well-being.A Happy Mouth Is a Happy Mind: FDI World Dental Federation features new song to raise awareness of the link between oral health and mental well-being.

A Happy Mouth Is a Happy Mind: FDI World Dental Federation features new song to raise awareness of the link between oral health and mental well-being.

GENEVA, March 20, 2025 /PRNewswire/ -- How does oral health affect mental well-being? This World Oral Health Day (WOHD), the…

1 month ago
TAHO Pharmaceuticals Reports Positive Results from Pivotal Study of TAH3311, the First Oral Dissolving Film AnticoagulantTAHO Pharmaceuticals Reports Positive Results from Pivotal Study of TAH3311, the First Oral Dissolving Film Anticoagulant

TAHO Pharmaceuticals Reports Positive Results from Pivotal Study of TAH3311, the First Oral Dissolving Film Anticoagulant

TAIPEI, Feb. 17, 2025 /PRNewswire/ -- TAHO Pharmaceuticals announces positive preliminary results from the pivotal study of TAH3311, the world's…

2 months ago
Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke ConferenceRecursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference

Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference

Met primary endpoint of safety and tolerability in CCM patients with no treatment-related discontinuations or Grade 3 adverse eventsIn comparison…

3 months ago
NADP Foundation Announces 2025 Grants to Advance Access to Oral HealthcareNADP Foundation Announces 2025 Grants to Advance Access to Oral Healthcare

NADP Foundation Announces 2025 Grants to Advance Access to Oral Healthcare

January 23, 2025 17:15 ET  | Source: National Association of Dental Plans DALLAS, Jan. 23, 2025 (GLOBE NEWSWIRE) -- The…

3 months ago
COLGATE INTRODUCES A SENSORY EXPERIENCE IN ORAL CARE WITH THE LAUNCH OF A NEW MAXFRESH RANGECOLGATE INTRODUCES A SENSORY EXPERIENCE IN ORAL CARE WITH THE LAUNCH OF A NEW MAXFRESH RANGE

COLGATE INTRODUCES A SENSORY EXPERIENCE IN ORAL CARE WITH THE LAUNCH OF A NEW MAXFRESH RANGE

MUMBAI, India, Dec. 23, 2024 /PRNewswire/ -- Colgate-Palmolive (India) Limited, the market leader in Oral Care, has unveiled a new…

4 months ago
COLGATE INTRODUCES A SENSORY EXPERIENCE IN ORAL CARE WITH THE LAUNCH OF A NEW MAXFRESH RANGECOLGATE INTRODUCES A SENSORY EXPERIENCE IN ORAL CARE WITH THE LAUNCH OF A NEW MAXFRESH RANGE

COLGATE INTRODUCES A SENSORY EXPERIENCE IN ORAL CARE WITH THE LAUNCH OF A NEW MAXFRESH RANGE

MUMBAI, India, Dec. 23, 2024 /PRNewswire/ -- Colgate-Palmolive (India) Limited, the market leader in Oral Care, has unveiled a new…

4 months ago
Show more Posts